TFAP2C may also be associated with breast cancer prognosis: higher TFAP2C levels correlate with poor overall survival in unique ERα(+) and endocrine therapy-treated subgroups [21], and high tissue TFAP2C expression also contributes to the failure of anti-hormone treatments [22]. This evidence concerns the gene TFAP2C and breast cancer.